MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China.
Kidney Disease Center, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou 310027, China.
Biomater Sci. 2022 Jan 18;10(2):457-466. doi: 10.1039/d1bm01525g.
Inflammatory bowel disease (IBD) is related to excessive reactive oxygen species (ROS) and high expression of proinflammatory cytokines. An enzymatically active drug carrier that can simultaneously scavenge excessive ROS and deliver anti-inflammatory drugs to inhibit the production of inflammatory cytokines may lead to improved therapeutic effects. Herein, nanoparticles (NPs) that can target activated macrophages, remove ROS and release anti-inflammatory drugs are fabricated by loading budesonide (Bud) into dextran sulfate sodium (DSS)-coated hollow mesoporous manganese dioxide (hMnO) NPs. This strategy can treat IBD better through the synergistic effect of the ROS-scavenging hMnO carriers and anti-inflammatory drug by blocking the amplification effect of inflammation. In addition, compared with free Bud, the drug delivery system can reduce side effects of Bud and improve its treatment outcome at the same dosage. Therefore, this study provides a new method for the design of highly effective synergistic anti-inflammatory nanomedicines.
炎症性肠病（IBD）与过量的活性氧（ROS）和促炎细胞因子的高表达有关。一种具有酶活性的药物载体，能够同时清除过量的 ROS 并递送抗炎药物以抑制炎症细胞因子的产生，可能会带来更好的治疗效果。在此，通过将布地奈德（Bud）载入到葡聚糖硫酸钠盐（DSS）包覆的中空介孔二氧化锰（hMnO）纳米粒子中，制备了可以靶向激活的巨噬细胞、清除 ROS 并释放抗炎药物的纳米粒子（NPs）。这种策略可以通过阻断炎症的放大效应，通过 ROS 清除的 hMnO 载体和抗炎药物的协同作用，更好地治疗 IBD。此外，与游离的 Bud 相比，该药物递送系统可以减少 Bud 的副作用，并在相同剂量下提高其治疗效果。因此，本研究为设计高效协同抗炎纳米药物提供了一种新方法。
